DZIEDZIŃSKI, Dawid, ŁOŚ, Dawid, NOWAK, Aleksandra, JANUS, Anita and KAPTUR, Agata. Progeria - the old children. Quality in Sport. 2024;15:52452. eISSN 2450-3118.
https://dx.doi.org/10.12775/QS.2024.15.52452
https://apcz.umk.pl/QS/article/view/52452

The journal has had 20 points in Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 12.06.2024. Revised: 20.06.2024. Accepted: 01.07.2024. Published: 08.07.2024.

Progeria - the old children

Dawid Dziedziński

Medical University of Lodz, al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland

https://orcid.org/0009-0003-9926-6772

dawidd0330@gmail.com

Dawid Łoś

M. Kopernik Regional Multispecialty Oncology and Traumatology Center: Łódź 62 Pabianicka St, 93-513 Łódź, PL

https://orcid.org/0009-0000-9521-5335

dawidms.los@gmail.com

Aleksandra Nowak

Medical University of Lodz, al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland

https://orcid.org/0009-0006-5028-8550

aleksandranowak1518@gmail.com

Anita Janus
Medical University of Lodz, al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland
https://orcid.org/0009-0007-6081-3707
anitajanus13@gmail.com

Agata Kaptur
M. Kopernik Regional Multispecialty Oncology and Traumatology Center: Łódź 62 Pabianicka St, 93-513 Łódź, PL
https://orcid.org/0009-0004-2466-1652
agatakaptur@interia.pl

Abstract:

Introduction and Purpose: Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare genetic disorder characterized by accelerated aging in children. This research article aims to provide a comprehensive overview of progeria, including its etiology, symptoms, diagnosis, and treatment options. By synthesizing existing knowledge, this study seeks to enhance understanding and promote effective management strategies for individuals affected by this condition.

Description of the State of Knowledge: Progeria is an exceedingly rare genetic disorder, with an estimated incidence of approximately one in every 4 to 8 million births worldwide. It manifests early in childhood, leading to premature aging and a spectrum of associated health complications. The condition is primarily caused by a mutation in the LMNA gene, resulting in the production of a defective form of the protein lamin A. This abnormal protein disrupts the structural integrity of the cell nucleus, contributing to the characteristic features of progeria. Despite advances in medical research, there is currently no cure for progeria, and treatment options focus on managing symptoms and improving quality of life.

Summary: This research article provides a comprehensive overview of progeria, highlighting its genetic basis, clinical manifestations, diagnostic criteria, and therapeutic interventions. By elucidating the state of knowledge surrounding progeria, this study aims to facilitate early

detection, enhance medical care, and foster ongoing research efforts aimed at advancing treatment modalities for affected individuals.

Key Words: Progeria, Hutchinson-Gilford progeria syndrome, accelerated aging, premature aging

Introduction:

Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare genetic disorder that causes accelerated aging in children. First described in the late 19th century, progeria presents a significant challenge for affected individuals and their families due to its profound impact on health and longevity. This research article aims to explore the etiology, symptoms, diagnosis, and treatment options associated with progeria, with the ultimate goal of advancing medical knowledge and improving patient care.

Etiology:

The aetiology of progeria is attributed to a de novo point mutation on chromosome 1, affecting the LMNA gene, which encodes the lamin A protein. This mutation results in the production of a defective form of lamin A, designated progerin. Progerin provides a scaffolding for the cell nucleus and stabilises the membrane surrounding the cell nucleus. Its mutation causes a disruption in the structure and function of the cell nucleus, resulting in the premature ageing phenotypes observed in people with progeria. While the exact mechanisms underlying progerin-induced cellular dysfunction are complex and have yet to be fully elucidated, among the proposed contributing factors are abnormal nuclear morphology, altered gene expression patterns and impaired DNA repair mechanisms.

In a broader sense, progeria is defined as any syndrome associated with premature ageing. Unlike these disease entities, Hutchinson's and Gilford's progeria is not associated with malfunctioning DNA repair mechanisms. [1-7]

Symptoms:

The clinical manifestations of progeria are numerous and encompass a multitude of organ systems.

1. Growth Deficiency: Children with progeria often exhibit a slower rate of growth than their peers. Such individuals may exhibit a significant discrepancy in height compared to the average for their age.

2. Deficiencies: There are also delays or abnormalities in dental development. It is not uncommon for children with progeria to experience dental issues such as tooth decay.

3. Skin: The skin may be thin, rough, and parchment-like. Furthermore, the presence of wrinkles and discolouration may be observed. In some cases, there may be issues with wound healing.

4. Facial features: The characteristics of this phenotype include prominent wrinkles, narrowing of the temples, a small mouth, a large nose and a small chin.

5. In terms of hair, the following characteristics may be observed: The hair may be thin, brittle, and grey, and growth may be limited. Furthermore, hair loss is also a common occurrence.

6. The nails may also be affected, exhibiting a brittle and fragile quality. The nails may be brittle and fragile.

7. Musculoskeletal System: Children with progeria may exhibit diminished muscle strength and reduced mobility. Such individuals may be susceptible to skeletal problems such as osteoporosis.

8. Endocrine System: Progeria can affect the endocrine system, resulting in a range of endocrine disorders. For instance, thyroid dysfunction may manifest.

9. Cardiovascular System: Progeria is associated with an increased risk of cardiovascular diseases, including atherosclerosis, coronary artery disease and hypertension. This is a common cause of mortality associated with progeria.

The tenth organ is the organ of sight. In individuals with progeria, a number of visual organ problems may be present, including cataracts, nearsightedness, farsightedness, and macular degeneration.

11. Hearing organ: Conductive hearing loss is a prevalent phenomenon across all age groups, with low-frequency hearing loss being more prevalent than high-frequency hearing loss.
Motor and mental development are unremarkable.
Children with HGPS appear to have normal immune systems, as they respond as well as the general population when subjected to various infections.
The liver, kidneys, gastrointestinal tract, neurological system, and cognitive functions are all within the normal range.
[8-15]

Diagnosis:

The Hutchinson-Gilford progeria diagnosis is based on a combination of various factors, including clinical observations, laboratory tests and an evaluation of family history. The following steps are often employed in the process of diagnosing progeria:

1. The initial step in the diagnostic process is the clinical observation of the patient. The physician conducts a comprehensive medical history and a meticulous physical examination, during which he searches for distinctive characteristics of progeria, such as growth deficiency, premature aging of the skin, face, and hair.

2. Family History: The physician examines the patient's family history to ascertain the presence of progeria or other rare genetic diseases within the family.

3. Laboratory Tests: Blood tests are frequently conducted, including genetic analysis, which can assist in the identification of mutations in the LMNA (lamin A/C) gene, which is associated with Hutchinson-Gilford progeria. Genetic testing can assist in the confirmation of a diagnosis of progeria.

4. Imaging Tests: Your physician may order imaging tests, such as computed tomography (CT) or magnetic resonance imaging (MRI), to assess the condition of internal organs and bone structures and to rule out other diseases.

5. Cardiac Function Assessment: Given the increased risk of cardiovascular disease associated with progeria, your doctor may order heart tests such as an electrocardiogram (ECG) or echocardiogram to assess heart function and detect any abnormalities.

6. Specialist consultations: It may be necessary to consult with specialists such as a geneticist, cardiologist, endocrinologist or ophthalmologist in order to confirm the diagnosis and plan further management.

The diagnosis of Hutchinson-Gilford progeria can be challenging due to its rarity and the similarity of symptoms to the natural ageing process. However, a comprehensive clinical examination, genetic analysis and collaboration between different specialists are essential in order to establish a diagnosis and ensure appropriate patient care. [15-16]

Treatment:

Hutchinson-Gilford Progeria is a genetic disease for which there is no specific treatment that can completely stop the aging process. However, there are several treatment strategies that can help relieve symptoms, improve the patient's quality of life, and prevent complications. Here is a general treatment regimen for Hutchinson-Gilford Progeria:

1. Multidisciplinary care: Treatment of Progeria requires a team approach involving several specialists, including a geneticist, pediatrician, cardiologist, endocrinologist, physical therapist, ophthalmologist, and psychologist. Collaboration among these specialists is key to providing comprehensive patient care.

2 Monitoring and Treatment of Complications: Patients with Progeria require regular monitoring and treatment of possible complications, such as cardiovascular disease, skeletal problems, endocrine disorders, or vision problems.

3 Physical and Occupational Therapy: Physical therapy can help maintain or improve range of motion, muscle strength, and coordination in patients with Progeria. Occupational therapy can promote the development of functional and daily living skills.

4 Symptomatic Treatment: There are several treatment strategies to alleviate the symptoms of Progeria, such as the use of moisturizing lotions for skin care, corrective eyeglasses for vision correction, and pain medications for joint pain.

5 Healthy lifestyle: Adopting a healthy lifestyle that includes a balanced diet, regular physical activity, and avoiding harmful habits such as smoking can help maintain overall health and improve a patient's quality of life.

6 Psychological Support: Progeria can affect not only the physical health but also the mental health of the patient and his or her family. Therefore, it is important to provide psychological support for both the patient and their loved ones to cope with the emotional and mental difficulties associated with the disease.

It is important to remember that each patient with Progeria is an individual and treatment should be tailored to their individual needs and symptoms. Regular monitoring and multidisciplinary care are key to ensuring the best possible quality of life for patients with Hutchinson-Gilford Progeria. [17-23]

Statement of the authors' contribution

Conceptualization: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Methodology: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Software: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Check: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Formal analysis: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Investigation: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Resources, data curation: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Writing - rough preparation: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Writing - review and editing: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Visualization: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Supervision: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

Project administration: Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus, Agata Kaptur

All authors have read and agreed with the published version of the manuscript.

Funding Statement

The study did not receive special funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflict of Interest Statement

No conflict of interest.

List of references

[1] Ahmed MS, Ikram S, Bibi N, Mir A. Hutchinson-Gilford Progeria Syndrome: A Premature Aging Disease. Mol Neurobiol. 2018 May;55(5):4417-4427. doi: 10.1007/s12035-017-0610-7. Epub 2017 Jun 28. PMID: 28660486.

[2] Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015;132:249-64. doi: 10.1016/B978-0-444-62702-5.00018-4. PMID: 26564085.

[3] Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Xiong ZM, Tavarez UL, Davison LM, Gete YG, Mao X, Newby GA, Doherty SP, Narisu N, Sheng Q, Krilow C, Lin CY, Gordon LB, Cao K, Collins FS, Brown JD, Liu DR. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021 Jan;589(7843):608-614. doi: 10.1038/s41586-020-03086-7. Epub 2021 Jan 6. PMID: 33408413; PMCID: PMC7872200.

[4] Gonzalo S, Kreienkamp R, Askjaer P. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations. Ageing Res Rev. 2017 Jan;33:18-29. doi: 10.1016/j.arr.2016.06.007. Epub 2016 Jun 29. PMID: 27374873; PMCID: PMC5195863.

[5] Mozzini C. Progeria, atherosclerosis and clonal hematopoiesis: links and future perspectives. Mech Ageing Dev. 2020 Dec;192:111365. doi: 10.1016/j.mad.2020.111365. Epub 2020 Sep 29. PMID: 33007346.

[6] Kreienkamp R, Gonzalo S. Hutchinson-Gilford Progeria Syndrome: Challenges at Bench and Bedside. Subcell Biochem. 2019;91:435-451. doi: 10.1007/978-981-13-3681-2_15. PMID: 30888661.

[7] Rahman MM, Ferdous KS, Ahmed M, Islam MT, Khan MR, Perveen A, Ashraf GM, Uddin MS. Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach. Curr Gene Ther. 2021;21(3):216-229. doi: 10.2174/1566523221666210303100805. PMID: 33655857.

[8] Xu S, Jin ZG. Hutchinson-Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies. Trends Biochem Sci. 2019 Jul;44(7):561-564. doi: 10.1016/j.tibs.2019.03.010. Epub 2019 Apr 26. PMID: 31036409.

[9] Guilbert SM, Cardoso D, Lévy N, Muchir A, Nissan X. Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageing. Methods. 2021 Jun;190:3-12. doi: 10.1016/j.ymeth.2020.04.005. Epub 2020 Apr 9. PMID: 32278808.

[10] Sharma A, Swarnkar B, Sethuraman G. Hutchinson-Gilford progeria. BMJ Case Rep. 2023 Sep 18;16(9):e256203. doi: 10.1136/bcr-2023-256203. PMID: 37723091; PMCID: PMC10510932.

[11] Talukder P, Saha A, Roy S, Ghosh G, Dutta Roy D, Barua S. Progeria-a Rare Genetic Condition with Accelerated Ageing Process. Appl Biochem Biotechnol. 2023 Apr;195(4):2587-2596. doi: 10.1007/s12010-021-03514-y. Epub 2022 Apr 21. PMID: 35445924.

[12] Sinha JK, Ghosh S, Raghunath M. Progeria: a rare genetic premature ageing disorder. Indian J Med Res. 2014 May;139(5):667-74. PMID: 25027075; PMCID: PMC4140030.

[13] Piekarowicz K, Machowska M, Dzianisava V, Rzepecki R. Hutchinson-Gilford Progeria Syndrome-Current Status and Prospects for Gene Therapy Treatment. Cells. 2019 Jan 25;8(2):88. doi: 10.3390/cells8020088. PMID: 30691039; PMCID: PMC6406247.

[14] Kreienkamp R, Gonzalo S. Metabolic Dysfunction in Hutchinson-Gilford Progeria Syndrome. Cells. 2020 Feb 8;9(2):395. doi: 10.3390/cells9020395. PMID: 32046343; PMCID: PMC7072593.

[15] Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria

syndrome. Nature. 2003 May 15;423(6937):293-8. doi: 10.1038/nature01629. Epub 2003 Apr 25. PMID: 12714972; PMCID: PMC10540076.

[16] Badame AJ. Progeria. Arch Dermatol. 1989 Apr;125(4):540-4. PMID: 2649013.

[17] Saxena S, Shukla D. The pursuit of therapy for progeria. Aging (Albany NY). 2021 Jun 27;13(12):15697-15698. doi: 10.18632/aging.203254. Epub 2021 Jun 27. PMID: 34176790; PMCID: PMC8266361.

[18] Harhouri K, Frankel D, Bartoli C, Roll P, De Sandre-Giovannoli A, Lévy N. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. Nucleus. 2018 Jan 1;9(1):246-257. doi: 10.1080/19491034.2018.1460045. PMID: 29619863; PMCID: PMC5973194.

[19] Cisneros B, García-Aguirre I, De Ita M, Arrieta-Cruz I, Rosas-Vargas H. Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives. Arch Med Res. 2023 Jul;54(5):102837. doi: 10.1016/j.arcmed.2023.06.002. Epub 2023 Jun 28. PMID: 37390702.

[20] Benedicto I, Chen X, Bergo MO, Andrés V. Progeria: a perspective on potential drug targets and treatment strategies. Expert Opin Ther Targets. 2022 May;26(5):393-399. doi: 10.1080/14728222.2022.2078699. Epub 2022 May 19. PMID: 35575136.

[21] Villa-Bellosta R. New treatments for progeria. Aging (Albany NY). 2019 Dec 22;11(24):11801-11802. doi: 10.18632/aging.102626. Epub 2019 Dec 22. PMID: 31866585; PMCID: PMC6949067.

[22] Lian J, Du L, Li Y, Yin Y, Yu L, Wang S, Ma H. Hutchinson-Gilford progeria syndrome: Cardiovascular manifestations and treatment. Mech Ageing Dev. 2023 Dec;216:111879. doi: 10.1016/j.mad.2023.111879. Epub 2023 Oct 11. PMID: 37832833.

[23] Batista NJ, Desai SG, Perez AM, Finkelstein A, Radigan R, Singh M, Landman A, Drittel B, Abramov D, Ahsan M, Cornwell S, Zhang D. The Molecular and Cellular Basis of Hutchinson-Gilford Progeria Syndrome and Potential Treatments. Genes (Basel). 2023 Feb 27;14(3):602. doi: 10.3390/genes14030602. PMID: 36980874; PMCID: PMC10048386.